COVID-19: Two Years Later
The world is now more than two years past the initial outbreak of the COVID-19 pandemic, and it’s incredible how much the COVID testing landscape has changed in those two years. In the early days, testing supply shortages made it difficult for communities to quickly scale testing operations, causing long lines—and a concerning inability to accurately track the progress of the pandemic.
But governments and private industry made heroic efforts to create and deploy novel COVID testing options. Here at bioMérieux, researchers and scientists developed the BIOFIRE® Respiratory 2.1 (RP2.1) Panel—and received FDA emergency use authorization—within just 40 working days. The syndromic BIOFIRE RP2.1 Panel added targets for SARS-CoV-2 into an already broad respiratory pathogen panel.
In March 2021, the BIOFIRE RP2.1 Panel became the first COVID-19 test to receive authorization outside the FDA EUA pathway.
These days, many testing options are available to labs and the general public. But not all tests are created equal. And the resurgence of other respiratory pathogens emphasizes the utility of the syndromic approach to COVID-19 testing.